**Theranostic nanoparticles:** Chen and colleagues provide an overview of the current and prospective status of these multifunctional nanosystems, including challenges in highly specific targeting of tumors. . . . . ***Page 1919***

**Customer satisfaction:** Hicks offers perspective on results of surveys that seek the opinion of referring clinicians about oncologic $^{18}$F-FDG PET/CT reporting and previews an article on this topic in this issue of *JNM*. . . . . ***Page 1923***

**Perception of PET/CT misinterpretation:** Karantanis and colleagues detail results of a study designed to collect pertinent information from physicians referring patients for oncologic $^{18}$F-FDG PET/CT, with surprising findings about clinicians' most frequent complaint. . . . . ***Page 1925***

**DWI in whole-body PET/MR:** Grueneisen and colleagues assess the diagnostic benefit of diffusion-weighted imaging in an $^{18}$F-FDG PET/MR protocol for whole-body staging of women with primary or recurrent malignancies of the pelvis. . . . . ***Page 1930***

**International use of PET in DLBCL:** Carr and colleagues report on a multinational study of PET for risk stratification in diffuse large B-cell lymphoma and ask whether biologic and health care system diversity influence response as assessed by interim PET. . . . . ***Page 1936***

**$^{99m}$Tc-folate M2 macrophage plaque imaging:** Jager and colleagues explore the presence of activated macrophages in human atherosclerotic plaques with $^{99m}$Tc-folate imaging and evaluate whether this technique can discriminate between M1- and M2-like macrophage phenotypes. . . . . ***Page 1945***

**MBF methods for $^{82}$Rb:** Murthy and colleagues compare differences among multiple methods and models for quantification of myocardial blood flow and myocardial flow reserve using $^{82}$Rb PET and assess their impact on prognostic assessment in a large clinical dataset. . . . . ***Page 1952***

**PET and SPECT in dementia:** O'Brien and colleagues investigate the comparative diagnostic accuracy of $^{18}$F-FDG PET and HMPAO SPECT in individuals with Alzheimer disease or dementia with Lewy bodies. . . ***Page 1959***

**$^{123}$I-CLINDE SPECT:** Feng and colleagues provide a method for and documentation of quantification of translocator protein binding using SPECT and a promising ligand in patients with cerebral stroke or glioblastoma multiforme. . . . . ***Page 1966***

**$^{18}$F-mefway characterization:** Hillmer and colleagues examine in humans the in vivo cerebral binding profile and metabolism of this serotonin-1A receptor that is implicated in an array of neurologic and psychiatric disorders. . . . . ***Page 1973***

**Scintigraphic imaging of endocarditis:** Rouzet and colleagues compare the respective performances of $^{18}$F-FDG PET and leukocyte scintigraphy for diagnosis of prosthetic valve endocarditis in 39 patients. . . . . ***Page 1980***

**FACBC physiologic uptake:** Schuster and colleagues explore common physiologic uptake patterns, as well as incidental findings and variants, in patients who have undergone PET imaging with this synthetic amino acid analog. . . . . ***Page 1986***

**$^{11}$C-CURB dosimetry:** Boileau and colleagues investigate in humans the whole-body biodistribution and radiation dosimetry of this novel $^{11}$C-labeled suicide irreversible tracer developed as a surrogate measure of activity of the fatty acid amide hydrolase. . . . . ***Page 1993***

**Dose reduction using SUV:** Cheng and colleagues explore how the injected $^{18}$F-FDG dose can be lowered while maintaining validity in comparing standardized uptake values between studies. . . . . ***Page 1998***

**Multimodality imaging of dementia:** Nazrallah and Wolk provide an educational overview of imaging in neurodegenerative dementia, including a focus on the potential for hybrid PET/MR imaging to improve diagnosis and management. . . . . ***Page 2003***

**Specific activity of antibody cocktails:** Pasternack and colleagues look at ways in which combinations of radiolabeled antibodies can be formulated to overcome the limitations of nonuniform dose distributions among disseminated tumor cells in targeted α therapy. . . . . ***Page 2012***

**$^{188}$Re-P2045 and tumor growth:** Nelson and colleagues describe studies designed to determine whether this radiolabeled peptide analog of somatostatin can inhibit pancreatic tumor xenograft growth in a mouse model. . . . . ***Page 2020***

**Imaging DNA damage in breast cancer:** Cornelissen and colleagues investigate whether $^{111}$In-anti-γH2AX-TAT is able to detect the DNA damage response during mammary oncogenesis in mice. . . . . ***Page 2026***

**$^{89}$Zr-labeled immuno-PET and HCC:** Sham and colleagues assess the potential of $^{89}$Zr-conjugated F(ab′)2 fragments directed against glypican-3 as a diagnostic immuno-PET probe in hepatocellular carcinoma. . . . . ***Page 2032***

**$^{18}$F-FDG uptake in CRC with mutated *KRAS*:** Iwamoto and colleagues explore through in vivo and small-animal studies the mechanisms by which *KRAS* gene mutations, which occur in ~40% of colorectal cancers, increase $^{18}$F-FDG accumulation. . . . . ***Page 2038***

**Immuno-PET targeting of STEAP1:** Doran and colleagues describe preparation and evaluation of $^{89}$Zr-2109A, a radiotracer for PET derived from a fully humanized monoclonal antibody to cell surface protein 6 transmembrane epithelial antigen of prostate 1 in preclinical prostate cancer models. . . . . ***Page 2045***

**GRPR antagonists for prostate cancer PET:** Chatalic and colleagues compare 3 novel gastrin-releasing peptide receptor–targeted radiolabeled tracers for PET imaging of prostate cancer. . . . . ***Page 2050***

**$^{99m}$Tc-peptide melanoma imaging:** Guo and Miao examine the effects of amino acid, hydrocarbon, and polyethylene glycol linkers on the melanoma targeting and imaging properties of several novel $^{99m}$Tc-labeled peptides. . . . . ***Page 2057***

**Myocardial perfusion IQ SPECT:** Caobelli and colleagues establish the lower limit of radioactivity that can be administered to patients for myocardial perfusion IQ SPECT and the minimum acquisition time that will preserve diagnostic accuracy. . . . . ***Page 2064***

**PET AC from MR:** Roy and colleagues detail a PET attenuation correction method using a patch-matching approach to synthesize CT images from ultrashort echo-time MR images, with resulting improvements in PET reconstruction accuracy. . . . . ***Page 2071***